Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies

Cancer

Volumn 98, Issue 3, 2003, Pages 610-617

  Fracasso, Paula M ^a,b   Rodriguez, Luis C ^a,b   Herzog, Thomas J ^a,b   Fears, Carole L ^a,b   Goodner, Sherry A ^a,b   Govindan, Ramaswamy ^a,b   Picus, Joel ^a,b   Rader, Janet S ^a,b   Tan, Benjamin R ^a,b   Arquette, Matthew A ^a,b  

^a USA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Accelerated titration design; Docetaxel; Pegylated liposomal doxorubicin; Phase I

Indexed keywords

DOCETAXEL; DOXORUBICIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG EFFICACY; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; MALAISE; MALE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; LIPOSOMES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; POLYETHYLENE GLYCOLS; TAXOIDS; TREATMENT OUTCOME;

EID: 0038298485     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11547     Document Type: Article

References (26)

1. Gabizon A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 2001;19:424-436.
2. Waterhouse DN, Tardi PG, Mayer LD, et al. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Safety. 2001;24:903-920.
3. Symon Z, Peyser A, Tzemach D, et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer. 1999;24:337-344.
4. Northfelt D, Dezube B, Thommes J, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998;16:2445-2451.
5. Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer. 2000;89:1037-1047.
6. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol. 1995;13:1777-1785.
7. 2. Ann Oncol. 2000;11:1029-1033.
8. Campos SM, Penson RT, Mays AR, et al. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol. 2000;81:206-212.
9. Sparano J, Winer E. Liposomal anthracyclines for breast cancer. Semin OncoL 2001;28:32-40.
10. Cortes J, Pazdur R. Docetaxel. J Clin Oncol. 1995;13:2643-2655.
11. Hainsworth J, Burris H 3rd, Erland J, et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 1998;16:2164-2168.
12. Ki Hong W. The current status of docetaxel in solid tumors. Oncology. 2002;16 (suppl):9-15.
13. Mamounas E, Sledge G. Combined anthracycline-taxane regimens in the adjuvant setting. Semin Oncol 2001;28:24-31.
14. Baker AF, Dorr RT. Drug interactions with the taxanes: clinical implications. Cancer Treat Rev. 2001;27:221-233.
15. Simon R, Freidlin B, Rubinstein L, et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst Cancer Spectrum. 1997;89:1138-1147.
16. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;9:710-717.
17. Itoh K, Sasaki Y, Fujii H, et al. Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer. Clin Cancer Res. 2000;6:4082-4090.
18. Baker SD, Kennedy MJ, Wolff AC, et al. Pharmacokinetics of doxorubicin and docetaxel combination in patients with advanced cancer [abstract]. Proc Am Soc Clin Oncol. 2001;20:109a.
19. Bellott R, Dieras RV, Misset JL, et al. Taxotere does not change the pharmacokinetic profile of doxorubicin and doxorubicinol [abstract]. Proc Am Soc Clin Oncol. 1998;17:221a.
20. Schuller J, Czejka M, Kletzl H, et al. Doxorubicin and taxotere: a pharmacokinetic study of the combination in advanced breast cancer [abstract]. Proc Am Soc Clin Oncol. 1998;17:205a.
21. Sparano JA, Malik U, Rajdev L, et al. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol. 2001;19:3117-3125.
22. Drinkard LC, Blumenschein GR, DiStefano A, et al. A phase I trial of liposomal doxorubicin (Doxil) given on day one followed by docetaxel (Taxotere) given on day five in patients with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol. 1999;18:209a.
23. Hirsch R, Jahanzeb M. Phase I study of Doxil in combination with escalating doses of Taxotere in the treatment of patients with advanced malignancies [abstract]. Proc Am Soc Clin Oncol. 1999;18:213a.
24. Wasserheit C, Downey A, Sorich J, et al. A phase I study of Taxotere and Doxil in patients with advanced malignancies [abstract]. Proc Am Soc Clin Oncol. 1999;18:167a.
25. Lopez F, Sikov WM. Phase I studies of weekly docetaxel with doxil or weekly doxorubicin [abstract]. Proc Am Soc Clin Oncol. 2000;19:213a.
26. Gasparini G, Morabito A, Fanelli M, et al. Phase I-II study of liposomal doxorubicin and docetaxel as first-line treatment in patients with advanced breast cancer [abstract]. Proc Am Soc Clin Oncol. 2002;21:546.